Comparison of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus.
Launched by RENNES UNIVERSITY HOSPITAL · Sep 8, 2005
Trial Information
Current as of June 08, 2025
Completed
Keywords
ClinConnect Summary
Recommendations for the prevention of transmission of resistant bacteria in intensive care units (ICU) are rarely based on controlled trials. For this reason, we compared a reinforced isolation precautions protocol (RIPP) with a standard precautions protocol (SPP) for the acquisition of methicillin-resistant Staphylococcus aureus (MRSA) in 2 intensive care units.
Evaluation: the risk for MRSA carriage was defined on admission if 1 of 3 criteria were met: hospitalization in the past year, transfer with prior length of stay ≥2 days, prior history of MRSA in the 5 past years.
Intervention: R...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults over 18 years
- • Expected length of stay \> 48h in intensive care unit
- • Informed written consent
- Exclusion Criteria:
- • Cerebral death
- • Care limitation
- • Neutropenia
- • Documented MRSA on admission
- • Patients receiving antistaphylococcal topical antibiotics on admission
About Rennes University Hospital
Rennes University Hospital, a leading academic medical center in France, is dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific research with clinical practice, fostering collaboration among multidisciplinary teams. Its commitment to excellence is reflected in its robust infrastructure and expertise in various medical fields, enabling the development and evaluation of novel therapies and treatment protocols. By participating in clinical trials, Rennes University Hospital aims to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rennes, , France
Tours, , France
Patients applied
Trial Officials
Christophe Camus, MD
Principal Investigator
Rennes University Hospital
Eric Bellissant, MD, PhD
Study Chair
Rennes University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials